Hongui Cha
YOU?
Author Swipe
View article: 178O A pan-tissue atlas of T cells during tumorigenesis reveals pre-cancer interception targets
178O A pan-tissue atlas of T cells during tumorigenesis reveals pre-cancer interception targets Open
View article: 22MO Exploiting neoantigen reactive CD8 T cell dysfunction to intercept lung squamous carcinogenesis
22MO Exploiting neoantigen reactive CD8 T cell dysfunction to intercept lung squamous carcinogenesis Open
View article: Abstract 2207: Intratumoral bacteria predict survival in clear cell renal cell carcinoma (ccRCC)
Abstract 2207: Intratumoral bacteria predict survival in clear cell renal cell carcinoma (ccRCC) Open
Background: ccRCC is marked by niches of immune evasion in late-stage disease, that are associated with resistance to immune checkpoint inhibitors (CPI). Intratumoral microbes are emerging as key modulators of the tumor immune microenviron…
View article: Author Correction: Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types
Author Correction: Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types Open
View article: Data from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Data from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Oncogenic KRAS impairs antitumor immune responses. As effective strategies to combine KRAS inhibitors and immunotherapies have so far proven elusive, a better understanding of the mechanisms by which oncogenic KRAS drives immune evasion is…
View article: Supplementary Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 4. COX-2 deficient tumors are sensitized to anti-tumor immunity
View article: Supplementary Table 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Table 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Table S3. sgRNA sequences for CRISPR-Cas9 gene knockout
View article: Supplementary Figure 9 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 9 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 9. Oncogenic KRAS drives tumor-intrinsic expression of COX-2 in LUAD
View article: Supplementary Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 2. KRAS-driven inhibition of tumor-intrinsic IFN signaling promotes immune evasion
View article: Figure 6 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 6 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Oncogenic KRAS drives immunosuppressive COX2 expression in lung adenocarcinoma. A, Immunoblot for COX2 (left) and ELISA analysis for PGE2 concentration (right) in KPAR cells treated with 10 nmol/L trametinib (MEKi) for 24 hours or 4…
View article: Supplementary Figure 8 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 8 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 8. COX-2/PGE2 pathway inhibition remodels the TME and enhances the efficacy of ICB
View article: Figure 6 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 6 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Oncogenic KRAS drives immunosuppressive COX2 expression in lung adenocarcinoma. A, Immunoblot for COX2 (left) and ELISA analysis for PGE2 concentration (right) in KPAR cells treated with 10 nmol/L trametinib (MEKi) for 24 hours or 4…
View article: Supplementary Figure 5 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 5 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 5. Flow cytometry gating strategies
View article: Supplementary Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 3. Oncogenic KRAS inhibits tumor-intrinsic IFN responses via Myc
View article: Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
COX2 inhibition enhances the efficacy of immunotherapy. A, Surface expression [mean fluorescence intensity (MFI)] of CD86 (left) and MHC II (right) on CD11b+ macrophages and CD11c+ macrophages in KPAR tumors tr…
View article: Supplementary Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 3. Oncogenic KRAS inhibits tumor-intrinsic IFN responses via Myc
View article: Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Tumor-intrinsic COX2 suppresses antitumor immunity. A, Kaplan–Meier survival of mice treated with 200 μg anti-NK1.1 and/or 200 μg anti-CD8 or corresponding isotype control (n = 5–7 per group) after orthotopic transplantation …
View article: Supplementary Table 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Table 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Table S2. Antibodies used for FACS analysis of mouse tumors
View article: Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
COX2 inhibition enhances the efficacy of immunotherapy. A, Surface expression [mean fluorescence intensity (MFI)] of CD86 (left) and MHC II (right) on CD11b+ macrophages and CD11c+ macrophages in KPAR tumors tr…
View article: Figure 5 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 5 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Dual inhibition of EP2 and EP4 synergizes with ICB. A–C, M1/M2 macrophage ratio (A), percentage of Arg1+ CD11b+ TAMs (B), and percentage of CD69+ CD8+ T cells (C) in K…
View article: Supplementary Figure 8 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 8 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 8. COX-2/PGE2 pathway inhibition remodels the TME and enhances the efficacy of ICB
View article: Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
In vivo CRISPR–Cas9 screen identifies regulators of antitumor immunity. A, Schematic of pooled CRISPR–Cas9 screen. B, sgRNAs targeting genes depleted in vitro compared with nontarget controls. The CRISPR score i…
View article: Supplementary Figure 7 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 7 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Supplementary Figure 7. Genetic loss of COX-2 signaling synergizes with ICB
View article: Figure 5 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 5 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Dual inhibition of EP2 and EP4 synergizes with ICB. A–C, M1/M2 macrophage ratio (A), percentage of Arg1+ CD11b+ TAMs (B), and percentage of CD69+ CD8+ T cells (C) in K…
View article: Supplementary Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
In vivo screen identifies mediators of immune resistance and sensitivity
View article: Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
COX2/PGE2 signaling hinders response to ICB in mouse and human lung adenocarcinoma. A, Kaplan–Meier survival of mice treated intraperitoneally with 200 μg anti-PD1 after orthotopic transplantation of KPAR or Ptgs2−/
View article: Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
In vivo CRISPR–Cas9 screen identifies regulators of antitumor immunity. A, Schematic of pooled CRISPR–Cas9 screen. B, sgRNAs targeting genes depleted in vitro compared with nontarget controls. The CRISPR score i…
View article: Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
Tumor-intrinsic COX2 suppresses antitumor immunity. A, Kaplan–Meier survival of mice treated with 200 μg anti-NK1.1 and/or 200 μg anti-CD8 or corresponding isotype control (n = 5–7 per group) after orthotopic transplantation …
View article: Supplementary Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Supplementary Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
In vivo screen identifies mediators of immune resistance and sensitivity
View article: Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Open
COX2/PGE2 signaling hinders response to ICB in mouse and human lung adenocarcinoma. A, Kaplan–Meier survival of mice treated intraperitoneally with 200 μg anti-PD1 after orthotopic transplantation of KPAR or Ptgs2−/